1-苄氧羰基-4-羟基-4-苯基哌啶 | 31637-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄氧羰基-4-羟基-4-苯基哌啶
• 英文名称: benzyl 4-hydroxy-4-phenylpiperidine-1-carboxylate
• 英文别名: 1-Benzyloxycarbonyl-4-phenyl-4-piperidinol；1-benzyloxycarbonyl-4-hydroxy-4-phenylpiperidine；1-CBZ-4-hydroxy-4-phenylpiperidine；4-hydroxy-4-phenyl-piperidine-1-carboxylic acid benzyl ester
• CAS: 31637-11-3
• 化学式: C₁₉H₂₁NO₃
• 分子量: 311.381
• InChiKey: SDTVUXKHYUZLJY-UHFFFAOYSA-N

物化性质

• 熔点：
  83-85 °C
• 沸点：
  481.7±45.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-苄氧羰基-4-羟基-4-苯基哌啶 在 palladium on activated charcoal 、 四氧化锇 sodium tetrahydroborate 、 N-甲基吲哚酮 、 jones reagent 、 次氯酸叔丁酯 、 三氟化硼乙醚 、 氢气 、 sodium hydride 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 丙酮 、 乙腈 、 叔丁醇 为溶剂， 反应 63.09h， 生成 (±)-coerulescine
  参考文献：
  名称：

  Synthesis of (±)-coerulescine and a formal synthesis of (±)-horsfiline

  摘要：

  A straightforward synthesis of (+/-)-coerulescine and (+/-)-horsfiline has been established from 3-formyl-3-phenylpyrridine employing 4-hydroxypiperidine as the starting material. There are two remarkable steps for the synthesis of (+/-)-coerulescine and ()-horsfiline. One is the rapid access to produce 3-formyl-3-phenylpyrrolidine by Lewis acid-catalyzed rearrangement of 3,4-dihydroxy-4-phenylpiperidine. The other key step is an intramolecular electrophilic cyclization from 3-benzylcarbamoyl-3-plienylpyrrolidine to the 3,3-spirocyclic 2-oxindole ring skeleton. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.10.015
• 作为产物：
  描述：

  4-羟基-1-哌啶甲酸苄酯 在 jones reagent 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 2.25h， 生成 1-苄氧羰基-4-羟基-4-苯基哌啶
  参考文献：
  名称：

  Synthesis of (±)-coerulescine and a formal synthesis of (±)-horsfiline

  摘要：

  A straightforward synthesis of (+/-)-coerulescine and (+/-)-horsfiline has been established from 3-formyl-3-phenylpyrridine employing 4-hydroxypiperidine as the starting material. There are two remarkable steps for the synthesis of (+/-)-coerulescine and ()-horsfiline. One is the rapid access to produce 3-formyl-3-phenylpyrrolidine by Lewis acid-catalyzed rearrangement of 3,4-dihydroxy-4-phenylpiperidine. The other key step is an intramolecular electrophilic cyclization from 3-benzylcarbamoyl-3-plienylpyrrolidine to the 3,3-spirocyclic 2-oxindole ring skeleton. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.10.015

文献信息

• Catalytic Friedel‐Crafts Reactions on Saturated Heterocycles and Small Rings for sp ³ ‐sp ² Coupling of Medicinally Relevant Fragments
  作者：Rosemary A. Croft、Maryne A. J. Dubois、Alexander J. Boddy、Camille Denis、Anna Lazaridou、Anne Sophie Voisin‐Chiret、Ronan Bureau、Chulho Choi、James J. Mousseau、James A. Bull

  DOI：10.1002/ejoc.201900498

  日期：2019.9

  A systematic comparison of Lewis acid catalysts [Ca(II), Li(I) and Fe(III)] is presented for catalytic Friedel–Crafts reactions using alcohols on 4‐, 5‐, and 6‐membered oxygen and nitrogen heterocycles and cyclobutanes, forming gem‐diaryl quaternary centers.

  路易斯酸催化剂[Ca（II），Li（I）和Fe（III）]的系统比较被提出用于使用醇在4、5和6元氧和氮杂环和环丁烷上进行的催化Friedel-Crafts反应，形成宝石-二芳基四元中心。
• Substituted piperidines as melanocortin-4 receptor agonists
  申请人：Merck & Co., Inc.

  公开号：US06350760B1

  公开（公告）日：2002-02-26

  Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.

  某些新型替代哌啶化合物是人类黑色素皮质素受体的激动剂，特别是人类黑色素皮质素-4受体（MC-4R）的选择性激动剂。因此，它们对于治疗、控制或预防对MC-4R激活敏感的疾病和紊乱是有用的，例如肥胖症、糖尿病、性功能障碍，包括勃起功能障碍和女性性功能障碍。还提供了使用对MC-4R具有选择性激动剂的化合物治疗性功能障碍的方法，而不是其他任何人类黑色素皮质素受体。
• Aryl substituted heterocycles
  申请人：Zeneca Limited

  公开号：US05654299A1

  公开（公告）日：1997-08-05

  The present invention concerns the novel use of aryl substituted heterocycles of formula I, set out below, which antagonize the pharmacological actions of one of ent endogenous neuropeptide tachykinins an the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment. Certain novel aryl substituted heterocycles of formula I and novel intermediates for their manufacture are also provided. ##STR1##

  本发明涉及下面列出的式I的芳基取代杂环化合物的新用途，这些化合物拮抗一种内源性神经肽激肽素和神经激肽2（NK2）受体的药理作用，使其在需要这种拮抗作用的情况下非常有用，例如在治疗哮喘和相关疾病时。该发明还提供了含有这些芳基取代杂环化合物的药物组合物，用于这种治疗。还提供了某些新型的式I的芳基取代杂环化合物以及用于它们制备的新型中间体。
• 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
  申请人：ZENECA LIMITED

  公开号：EP0630887A1

  公开（公告）日：1994-12-28

  The present invention concerns the novel aryl substituted heterocycles of formula I, set out below, wherein R², R³ and R⁴ have the values defined herein, which antagonize the pharmacological actions of one of the endogenous neuropeptide tachykinins at the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment, methods for their use, and processes and novel intermediates for their manufacture.

  本发明涉及如下式 I 的新型芳基取代杂环，其中 R²、R³ 和 R⁴ 具有本文所定义的值，该杂环可拮抗内源性神经肽之一速激肽在神经激肽 2 (NK2) 受体上的药理作用，因此在需要这种拮抗作用时，例如在治疗哮喘和相关病症时，它们是有用的。 本发明还提供了用于此类治疗的含有芳基取代杂环的药物组合物、使用方法以及生产工艺和新型中间体。
• US5654299A
  申请人：——

  公开号：US5654299A

  公开（公告）日：1997-08-05